Leading the Way in Life Science Technologies

GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

FDA Offers Clues to How It Will Pave the Way to Getting Biosimilars on the Market

Paper in NEJM divulged the broad strokes of agency’s plans, but nuts and bolts are still up in the air.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »